Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of the vaccinia virus. Olvi-Vec, our lead product candidate is currently in a Phase 3 registrational clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also being developed in Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer.
We are dedicated to advancing a pipeline of next-generation oncolytic immunotherapies that deliver the full complement of tumor neo-antigens with the power to stimulate a personalized immune response for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here.
For more information, please visit https://genelux.com/ and follow us on Twitter @Genelux_Corp and Facebook @Genelux.
Olvi-Vec is an investigational product candidate not yet approved by the US Food and Drug Administration.
Company Details
- Employees
- 33
- Founded
- 2001
- Address
- Westlake Village, California, Us
- Phone
- 8584830026
- in****@****lux.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- kinofistpix.com
- Keywords
- Manager jobs.
- HQ
- Westlake Village, California
Genelux Questions
Genelux's helpline number is 8584830026
Genelux's website is kinofistpix.com
Genelux's LinkedIn profile is https://www.linkedin.com/company/genelux
Genelux has
33 employees.
View email and phone details for 33
employees at Genelux.
Genelux's industry is
Biotechnology Research
Genelux's support email address is info@genelux.com
Genelux's categories are Biotechnology Research
Genelux's founding year is 2001
